Intravenous vs. Oral Trazodone in the Management of Withdrawal Symptoms in Psychiatric Inpatients: A Naturalistic Study
Clinical Neuropsychopharmacology and Addiction · 2025
DOI: 10.53941/cna.2025.100005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Neuropsychopharmacology and Addiction, 2025. Verfasst von Miriam Olivola und 8 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Trazodone, a serotonin antagonist and reuptake inhibitor (SARI), is frequently used off-label in psychiatric settings to manage insomnia, agitation, and withdrawal symptoms in patients with Substance Use Disorders (SUD). While the oral formulation is widely adopted, intravenous (IV) trazodone may provide faster onset, better tolerability, and greater clinical efficacy in acute care.
Methods
This naturalistic observational study compared the short-term efficacy and safety of oral versus IV trazodone in 100 psychiatric inpatients with a primary DSM-5-TR diagnosis of SUD, including alcohol, benzodiazepines, opioids, cocaine, or polysubstance use. Patients were consecutively admitted to the SPDC of Pavia between January and October 2024. Fifty patients received oral trazodone (up to 300 mg/day), and fifty received IV trazodone (50 mg TID, totaling 150 mg/day) for a minimum of five days. Efficacy was evaluated using the Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA-Ar) and a Visual Analogue Scale (VAS) for craving. Tolerability and safety were assessed with the UKU Side Effect Rating Scale and systematic monitoring of blood pressure and QTc intervals.
Results
IV trazodone was associated with a significantly greater reduction in withdrawal symptoms (CIWA-Ar mean Δ: 14.8 vs. 9.2; p < 0.001), as well as stronger craving reduction (p = 0.017), and a higher rate of clinically significant improvement (86% vs. 62%; p = 0.012). The IV group also showed fewer adverse effects, including lower incidence of sedation (p = 0.028) and orthostatic hypotension (p = 0.041). No clinically relevant QTc prolongation was observed in either group.
Conclusions
IV trazodone demonstrated superior efficacy and tolerability compared to its oral formulation for the short-term management of SUD-related withdrawal symptoms. These findings support its potential use as a viable alternative in acute psychiatric care, particularly when rapid stabilization is required and benzodiazepine use is limited or contraindicated.
Zitieren
APA
Olivola, M., Mazzoni, F., Prodi, T., Versaci, G., Miacca, G. C., Guffanti, A., Martiadis, V., Brondino, N., & Dell’Osso, B. M. (2025). Intravenous vs. Oral Trazodone in the Management of Withdrawal Symptoms in Psychiatric Inpatients: A Naturalistic Study. Clinical Neuropsychopharmacology and Addiction. https://doi.org/10.53941/cna.2025.100005
Vancouver
Olivola M, Mazzoni F, Prodi T, Versaci G, Miacca GC, Guffanti A, et al. Intravenous vs. Oral Trazodone in the Management of Withdrawal Symptoms in Psychiatric Inpatients: A Naturalistic Study. Clinical Neuropsychopharmacology and Addiction. 2025. doi:10.53941/cna.2025.100005
BibTeX
@article{Olivola2025,
author = {Olivola, Miriam and Mazzoni, Filippo and Prodi, Tiziano and Versaci, Giada and Miacca, Giovanni Carnevale and Guffanti, Alessandro and Martiadis, Vassilis and Brondino, Natascia and Dell’Osso, Bernardo Maria},
title = {Intravenous vs. Oral Trazodone in the Management of Withdrawal Symptoms in Psychiatric Inpatients: A Naturalistic Study},
journal = {Clinical Neuropsychopharmacology and Addiction},
year = {2025},
doi = {10.53941/cna.2025.100005}
}
EUVIMED